PRESS RELEASE published on 04/27/2023 at 07:30, 1 year 11 months ago Formycon publishes results for financial year 2022
PRESS RELEASE published on 04/25/2023 at 07:00, 1 year 11 months ago Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
PRESS RELEASE published on 02/07/2023 at 07:30, 2 years 2 months ago Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG
PRESS RELEASE published on 02/06/2023 at 07:30, 2 years 2 months ago Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study
PRESS RELEASE published on 02/02/2023 at 08:00, 2 years 2 months ago Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
PRESS RELEASE published on 02/02/2023 at 07:30, 2 years 2 months ago EQS-Adhoc: Formycon AG announces result of private placement and sets placement price for the new shares from the capital increase
PRESS RELEASE published on 02/01/2023 at 23:30, 2 years 2 months ago EQS-Adhoc: Formycon AG upsizes capital increase from authorized capital following strong demand
PRESS RELEASE published on 02/01/2023 at 17:40, 2 years 2 months ago EQS-Adhoc: Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
PRESS RELEASE published on 02/01/2023 at 17:40, 2 years 2 months ago EQS-Adhoc: Formycon AG plans capital increase of approx. 5% of the share capital by way of an accelerated bookbuilding procedure to finance further growth
PRESS RELEASE published on 01/09/2023 at 13:05, 2 years 3 months ago EQS-Adhoc: Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea®1, in the United States
Published on 04/18/2025 at 23:35, 1 day 9 hours ago urban-gro, Inc. Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
Published on 04/18/2025 at 01:20, 2 days 7 hours ago Aston Bay Files Technical Report for Storm Copper Project Initial Mineral Resource Estimate
Published on 04/18/2025 at 00:00, 2 days 8 hours ago Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology
Published on 04/18/2025 at 18:00, 1 day 14 hours ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.03.25.
Published on 04/18/2025 at 17:54, 1 day 14 hours ago VALBIOTIS SA: Compte-rendu de l’Assemblée générale mixte du 18 avril 2025
Published on 04/18/2025 at 17:52, 1 day 14 hours ago Market entry in France – Cicor acquires significant business activities of Éolane
Published on 04/18/2025 at 17:45, 1 day 15 hours ago Linedata Services: Déclaration des transactions sur actions propres opération du 16 avril 2025
Published on 04/18/2025 at 17:45, 1 day 15 hours ago Saint-Gobain once again featured on CDP’s “Climate A List”
Published on 04/18/2025 at 17:45, 1 day 15 hours ago Saint-Gobain figure une nouvelle fois sur la « Climate A List » établie par le CDP
Published on 04/18/2025 at 11:16, 1 day 21 hours ago Déclaration hebdomadaire d'opérations effectuées du 14 au 17 avril 2025
Published on 04/18/2025 at 11:16, 1 day 21 hours ago Disclosure of transactions in own shares from April 14 to April 17, 2025
Published on 04/18/2025 at 07:00, 2 days 1 hour ago Uitnodiging voor de Jaarvergadering en Buitengewone Algemene Vergadering van aandeelhouders
